Manuela Valente Sells 3,824 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Manuela Valente sold 3,824 shares of SOPHiA GENETICS on April 8 at an average $4.85 (~$18,546) and has sold a total of 9,177 shares in recent trades; the April 8 sale was executed under a Rule 10b5-1 plan to cover tax withholding from vested awards, reducing her holdings to 215,451 shares (a 1.74% decrease).
• SOPH shares trade near $4.70 with a $321.9M market cap; the company reported an EPS miss (‑$0.28 vs. consensus ‑$0.20), negative margins and ROE, and carries a consensus analyst rating of Hold with a $7.00 target amid mixed buy/sell opinions.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Manuela Valente sold 3,824 shares of the business's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $4.85, for a total transaction of $18,546.40. Following the sale, the insider directly owned 215,451 shares in the company, valued at approximately $1,044,937.35. This represents a 1.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Tuesday, April 7th, Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,571.12.
• On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,595.45.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $1,820.20.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH traded down $0.03 during trading on Friday, hitting $4.70. 94,702 shares of the stock were exchanged, compared to its average volume of 184,971. The company has a market cap of $321.90 million, a PE ratio of -9.22 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The company has a fifty day moving average price of $4.76 and a two-hundred day moving average price of $4.68. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analysts' expectations of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. On average, analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on SOPH. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. BTIG Research restated a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Finally, Guggenheim lifted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.00.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in the stock. Alta Wealth Advisors LLC acquired a new stake in shares of SOPHiA GENETICS during the third quarter valued at $6,708,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth about $48,000. Federated Hermes Inc. boosted its stake in shares of SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock worth $682,000 after purchasing an additional 31,000 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of SOPHiA GENETICS by 169.5% during the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company's stock worth $388,000 after buying an additional 52,200 shares in the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.